Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€162.40

€162.40

0.000%
-
0.000%
€199.34
 
11:53 / Tradegate WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

AbbVie Inc. Stock

The AbbVie Inc. price is unchanged compared to yesterday.
With 45 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 199 € there is a positive potential of 22.54% for AbbVie Inc. compared to the current price of 162.4 €.
Our community identified positive and negative aspects for AbbVie Inc. stock for the coming years. 1 users see the criterium "Expected dividend yield" as a plus for the AbbVie Inc. stock. On the other hand our users think that "Debt" could be a problem in the future.

AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.

Pros and Cons of AbbVie Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of AbbVie Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
AbbVie Inc. 0.000% -1.695% 1.627% -0.098% -4.053% 11.677% 94.701%
Johnson & Johnson -0.150% 2.560% 10.056% 0.014% 3.710% -14.448% 13.361%
Elanco Animal Health Inc. -0.030% 0.112% 8.289% 6.262% 8.157% -38.153% -38.382%
Pfizer Inc. -1.160% 1.721% 3.033% -22.031% -14.978% -57.032% -29.831%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.

Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.

Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.

Comments

Prediction Buy
Perf. (%) -4.02%
Target price 189.648
Change
Ends at 29.04.26

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Guggenheim from $214.00 to $216.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.29%
Target price 180.544
Change
Ends at 28.04.26

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Evercore ISI from $204.00 to $205.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.10%
Target price 220.175
Change
Ends at 28.04.26

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $241.00 to $250.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

News

The 3 Things That Matter for AbbVie Now: https://g.foolcdn.com/editorial/images/825388/doctor-and-patient-talking.jpg
The 3 Things That Matter for AbbVie Now

It's been a challenging past three years for AbbVie (NYSE: ABBV). The pharmaceutical leader lost U.S. patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical

3 Dividend Growth Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/824621/woman-smiling-laptop.jpg
3 Dividend Growth Stocks to Buy and Hold

What's better than a great dividend? A great dividend that's growing.

Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare

The Smartest Dividend Stocks to Buy With $300 Right Now: https://g.foolcdn.com/editorial/images/824521/transmission-lines-with-2-workers.jpg
The Smartest Dividend Stocks to Buy With $300 Right Now

Are dividend stocks only for investors nearing or in retirement? Not at all. Consider that more than half of the S&P 500's (SNPINDEX: ^GSPC) total return over the last 50 years was due to